Atea Pharmaceuticals, Inc. (AVIR) Earnings History
Net Loss8 years of earnings data (2018–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Atea Pharmaceuticals, Inc. (AVIR) Earnings Overview
As of June 28, 2026, Atea Pharmaceuticals, Inc. (AVIR) reported trailing twelve-month net income of -$170M, reflecting +3.0% year-over-year growth. The company earned $-2.14 per diluted share over the past four quarters.
Looking at the long-term picture, AVIR's historical earnings data spans multiple years. The company achieved its highest annual net income of $121M in fiscal 2021.
Atea Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IOVA (-$354M net income, -148.4% margin), RDVT ($14M net income, 14.6% margin), RLAY (-$273M net income, -1800.6% margin), AVIR has comparable earnings metrics. Compare AVIR vs IOVA →
AVIR Earnings vs Peers
Earnings metrics vs comparable public companies
AVIR Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$158M | +6.0% | -$181M | $-1.94 | - | - |
| 2024 | -$168M | -23.9% | -$193M | $-2.00 | - | - |
| 2023 | -$136M | -17.3% | -$164M | $-1.63 | - | - |
| 2022 | -$116M | -195.6% | -$131M | $-1.39 | - | - |
| 2021 | $121M | +1207.1% | $138M | $1.37 | 34.5% | 39.4% |
| 2020 | -$11M | +18.7% | -$11M | $-0.13 | -22.5% | -22.7% |
| 2019 | -$13M | -48.5% | -$15M | $-0.16 | - | - |
| 2018 | -$9M | - | -$9M | $-0.90 | - | - |
Download Data
Export AVIR earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
AVIR — Frequently Asked Questions
Quick answers to the most common questions about buying AVIR stock.
What is AVIR earnings per share (EPS)?
AVIR trailing twelve-month (TTM) diluted EPS is $-2.14, reflecting +3.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2018 to 2025 is available in the table on this page.
What is Atea Pharmaceuticals, Inc.'s net income?
Atea Pharmaceuticals, Inc. (AVIR) trailing twelve-month net income is $-170M as of 2025. Earnings grew +3.0% year-over-year.
Is AVIR profitable?
AVIR is not currently profitable on a TTM basis, reporting a net loss of $-170M. Net margin is N/A. Investors should monitor for a return to profitability.
What is AVIR's earnings growth rate?
AVIR compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2018 to 2025.
What are AVIR's profit margins?
Atea Pharmaceuticals, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -44.3%.
Is AVIR growing earnings?
AVIR earnings growth is slowing. Current YoY EPS growth of +3.0% trails the 5-year CAGR of N/A. TTM net income is $-170M.
What was AVIR's best earnings year?
Atea Pharmaceuticals, Inc.'s highest annual net income on record is $121M, achieved in fiscal year 2021. Earnings history on this page spans 2018 to 2025 and includes all annual and quarterly figures.
What were AVIR's earnings last quarter?
AVIR's most recent reported quarter was Q1 2026. Net income was $-45M with diluted EPS of $-0.57. For a full breakdown of all quarters, see the quarterly earnings table on this page.